Search results
Results from the WOW.Com Content Network
Glibenclamide, also known as glyburide, is an antidiabetic medication used to treat type 2 diabetes. [1] It is recommended that it be taken together with diet and exercise. [1] It may be used with other antidiabetic medication. [1] It is not recommended for use by itself in type 1 diabetes. [1] It is taken by mouth. [1]
Hypoglycemia is the most common metabolic problem in newborns. [2] Neonatal hypoglycemia is hypothesized to occur in between 1 in 3 births out of every 1,000 births, but the true number is not known since there is no international standard for measurement. It often occurs in premature and small babies and babies of diabetic mothers.
Help; Learn to edit; Community portal; Recent changes; Upload file; Special pages
Pill and her family members spent over 30 minutes giving the infant CPR until the ambulance arrived at 5:09 a.m. Wyllow-Raine was taken to the hospital but was pronounced dead shortly after arriving.
Pleural effusions can also develop, which are also seen with meconium aspiration but not with respiratory distress syndrome. [2] The lungs may also appear hyperinflated. [5] It is a diagnosis of exclusion as it is a benign condition that can have symptoms and signs similar to more serious syndromes, such as respiratory distress or meconium ...
Vildagliptin, sold under the brand name Galvus and others, is an oral anti-hyperglycemic agent (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs.
[2] [1] A bilirubin level more than 34 μmol/L (2 mg/dL) may be visible. [1] Concerns, in otherwise healthy babies, occur when levels are greater than 308 μmol/L (18 mg/dL), jaundice is noticed in the first day of life, there is a rapid rise in levels, jaundice lasts more than two weeks, or the baby appears unwell. [1]
Alogliptin, sold under the brand names Nesina and Vipidia, [2] [3] is an oral anti-diabetic drug in the DPP-4 inhibitor (gliptin) class. [4] Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of hypoglycemia, and has relatively modest glucose-lowering activity. [1]